<s>
The_AT role_NN1 of_IO process_NN1 research_NN1 and_CC development_NN1 department_NN1 at_II AstraZeneca_NP1 is_VBZ to_TO discover_VVI and_CC develop_VVI robust_JJ ,_, economic_JJ manufacturing_NN1 processes_NN2 for_IF new_JJ chemical_JJ entities_NN2 ._. 
</s>
<s>
The_AT team_NN1 also_RR provides_VVZ supplies_NN2 of_IO drug_NN1 substances_NN2 to_TO fund_VVI development_NN1 programmes_NN2 and_CC to_TO provide_VVI chemical_JJ manufacturing_NN1 controls_VVZ documentation_NN1 to_TO satisfy_VVI external_JJ regulatory_JJ authorities_NN2 ._. 
</s>
<s>
The_AT equipment_NN1 used_VVN in_II the_AT scale_NN1 up_II lab/plant_NN1 is_VBZ not_XX that_DD1 dissimilar_JJ to_II the_AT type_NN1 of_IO vessel_NN1 used_VVN in_II a_AT1 discovery_NN1 lab_NN1 ._. 
</s>
<s>
However_RR to_TO describe_VVI process_NN1 chemistry_NN1 as_II bucket_NN1 chemistry_NN1 would_VM be_VBI incorrect_JJ and_CC to_TO assume_VVI that_CST it_PPH1 just_RR involves_VVZ scaling_VVG up_RP existing_JJ process_NN1 would_VM also_RR be_VBI an_AT1 incorrect_JJ description_NN1 ._. 
</s>
<s>
The_AT department_NN1 is_VBZ divided_VVN into_II five_MC parts_NN2 ;_; process_VV0 chemistry_NN1 ;_; process_VV0 analysis_NN1 ;_; development_NN1 manufacture_NN1 (_( pilot_NN1 plant_NN1 and_CC large_JJ scale_NN1 lab_NN1 )_) ;_; process_VV0 engineering_NN1 ;_; and_CC projects_NN2 management_NN1 ._. 
</s>
<s>
Each_DD1 of_IO these_DD2 plays_NN2 a_AT1 key_JJ role_NN1 during_II the_AT chemical_JJ development_NN1 of_IO a_AT1 new_JJ chemical_JJ entity_NN1 and_CC each_DD1 of_IO these_DD2 areas_NN2 employs_VVZ chemists_NN2 ._. 
</s>
<s>
The_AT process_NN1 chemistry_NN1 area_NN1 devises_VVZ the_AT final_JJ route_NN1 of_IO manufacture_NN1 and_CC optimises_VVZ the_AT chosen_JJ route_NN1 into_II a_AT1 viable_JJ manufacturing_NN1 process_NN1 ._. 
</s>
<s>
Process_VV0 analysts_NN2 develop_VV0 appropriate_JJ analytical_JJ methodology_NN1 to_TO assess_VVI the_AT purity_NN1 of_IO the_AT active_JJ pharmaceutical_JJ ingredient_NN1 (_( API_NP1 )_) and_CC the_AT intermediates_NN2 ,_, specifications_NN2 are_VBR set_VVN along_II the_AT process_NN1 chemists_NN2 of_IO intermediates_NN2 and_CC APIs_NP1 ,_, a_AT1 methodology_NN1 is_VBZ developed_VVN to_TO monitor_VVI reactions_NN2 to_TO help_VVI gain_VVI the_AT maximum_JJ amount_NN1 of_IO information_NN1 ._. 
</s>
<s>
Development_NN1 manufacture_NN1 are_VBR responsible_JJ for_IF running_VVG the_AT process_NN1 in_II the_AT pilot_NN1 plant_NN1 or_CC kilo-lab_NN1 ,_, they_PPHS2 work_VV0 closely_RR with_IW process_NN1 chemistry_NN1 to_TO ensure_VVI that_CST the_AT process_NN1 being_VBG developed_VVN is_VBZ compatible_JJ with_IW the_AT intended_JJ site_NN1 of_IO manufacture_NN1 ._. 
</s>
<s>
Process_VV0 engineering_NN1 help_NN1 with_IW plant_NN1 suitability_NN1 and_CC compatibility_NN1 ,_, help_VV0 decide_VVI between_II isolation_NN1 options_NN2 for_REX21 example_REX22 crystallisation_NN1 ,_, resolution_NN1 of_IO specific_JJ scale_NN1 up_II issues_NN2 for_REX21 example_REX22 agitation_NN1 and_CC heat/mass_VV0 transfer_NN1 ,_, and_CC make_VV0 sure_JJ engineering_NN1 problems_NN2 are_VBR not_XX solved_VVN using_VVG chemistry_NN1 ._. 
</s>
<s>
Project_NN1 management_NN1 is_VBZ the_AT link_NN1 between_II the_AT global_JJ project_NN1 teams_NN2 and_CC process_VV0 research_NN1 and_CC development_NN1 ;_; they_PPHS2 coordinate_VV0 pan-process_JJ research_NN1 and_CC development_NN1 activities_NN2 at_II a_AT1 high_JJ level_NN1 ._. 
</s>
<s>
The_AT interface_NN1 between_II process_NN1 research_NN1 and_CC development_NN1 and_CC other_JJ departments_NN2 for_IF a_AT1 particular_JJ project_NN1 is_VBZ overseen_VVN by_II project_NN1 management_NN1 along_II21 with_II22 various_JJ outsourcing_JJ activities_NN2 ._. 
</s>
<s>
Process_VV0 research_NN1 and_CC development_NN1 is_VBZ a_AT1 diverse_JJ area_NN1 ,_, there_EX are_VBR many_DA2 interactions_NN2 with_IW other_JJ departments_NN2 in_BCL21 order_BCL22 to_TO aid_VVI the_AT overall_JJ production_NN1 of_IO a_AT1 successful_JJ drug_NN1 ._. 
</s>
<s>
These_DD2 departments_NN2 include_VV0 discovery_NN1 ,_, regulatory_JJ ,_, formulation_NN1 ,_, drug_NN1 metabolism_NN1 ,_, manufacturing_NN1 ,_, safety_NN1 assessment_NN1 ,_, patent_NN1 and_CC marketing_NN1 ._. 
</s>
<s>
The_AT process_NN1 of_IO producing_VVG a_AT1 new_JJ drug_NN1 is_VBZ a_AT1 lengthy_JJ and_CC difficult_JJ process_NN1 ,_, from_II the_AT point_NN1 of_IO lead_NN1 identification_NN1 if_CS can_VM take_VVI up_RG21 to_RG22 3_MC years_NNT2 for_IF the_AT drug_NN1 discovery_NN1 team_NN1 to_TO develop_VVI a_AT1 candidate_NN1 for_IF selection_NN1 ._. 
</s>
<s>
The_AT next_MD stage_NN1 is_VBZ drug_NN1 development_NN1 ,_, which_DDQ is_VBZ where_RRQ process_NN1 research_NN1 and_CC development_NN1 fits_VVZ in_II this_DD1 can_VM take_VVI up_RG21 to_RG22 5_MC years_NNT2 ._. 
</s>
<s>
There_EX are_VBR three_MC phases_NN2 within_II this_DD1 ,_, phase_NN1 I_ZZ1% is_VBZ initial_JJ safety_NN1 and_CC clinical_JJ trials_NN2 ,_, phase_NN1 II_MC is_VBZ clinical_JJ trials_NN2 in_II patients_NN2 and_CC phase_NN1 III_MC is_VBZ wide_RR ranging_JJ trials_NN2 for_IF comparative_JJ efficiency_NN1 and_CC safety_NN1 prior_II21 to_II22 marketing_NN1 ._. 
</s>
<s>
When_CS all_DB this_DD1 is_VBZ completed_VVN the_AT drug_NN1 is_VBZ marketed_VVN and_CC launched_VVN ._. 
</s>
<s>
The_AT whole_JJ process_NN1 can_VM take_VVI in_II the_AT region_NN1 of_IO 15_MC years_NNT2 to_TO complete_VVI ._. 
</s>
<s>
Each_DD1 phase_NN1 of_IO drug_NN1 development_NN1 requires_VVZ a_AT1 differing_JJ quantity_NN1 of_IO the_AT selected_JJ drug_NN1 candidate_NN1 and_CC it_PPH1 is_VBZ the_AT job_NN1 of_IO process_NN1 research_NN1 and_CC development_NN1 to_TO produce_VVI a_AT1 route_NN1 which_DDQ is_VBZ viable_JJ to_TO synthesise_VVI the_AT drug_NN1 on_II these_DD2 scales_NN2 ;_; phase_NN1 I_PPIS1 requires_VVZ 5-10kg_NNU ,_, phase_NN1 II_MC 30-100kg_NNU and_CC phase_NN1 III_MC 100-500kg_NNU ._. 
</s>
<s>
Discovery_NN1 support_NN1 work_NN1 alongside_II process_NN1 research_NN1 and_CC development_NN1 to_TO reduce_VVI the_AT time_NNT1 it_PPH1 takes_VVZ to_TO identify_VVI the_AT final_JJ route_NN1 ,_, there_EX are_VBR two_MC ways_NN2 to_TO do_VDI this_DD1 ;_; scale_VV0 up_RP the_AT discovery_NN1 route_NN1 (_( which_DDQ generally_RR is_VBZ not_XX the_AT best_JJT way_NN1 to_TO approach_VVI this_DD1 )_) or_CC to_TO improve_VVI the_AT way_NN1 in_II which_DDQ the_AT best_JJT route_NN1 is_VBZ selected_VVN by_II starting_VVG earlier_RRR ._. 
</s>
<s>
It_PPH1 is_VBZ key_JJ for_IF discovery_NN1 and_CC process_VV0 to_TO collaborate_VVI -_- it_PPH1 is_VBZ this_DD1 collaboration_NN1 which_DDQ speeds_VVZ up_RP the_AT very_RG lengthy_JJ process_NN1 of_IO discovery_NN1 and_CC development_NN1 ._. 
</s>
<s>
The_AT supply_NN1 of_IO the_AT first_MD 1-5kg_JJ is_VBZ often_RR a_AT1 variant_NN1 of_IO the_AT discovery_NN1 route_NN1 ,_, however_RGQV once_RR 5kg_NNU has_VHZ been_VBN produced_VVN the_AT next_MD step_NN1 requires_VVZ 30kg_NNU ._. 
</s>
<s>
Generally_RR the_AT discovery_NN1 route_NN1 is_VBZ not_XX viable_JJ for_IF this_DD1 larger_JJR scale_NN1 production_NN1 so_RR in_II parallel_NN1 to_II manufacturing_VVG the_AT initial_JJ 5kg_NNU there_RL needs_VVZ to_TO be_VBI development_NN1 of_IO an_AT1 alternative_JJ route_NN1 or_CC the_AT discovery_NN1 route_NN1 needs_VVZ to_TO be_VBI dropped_VVN all_DB together_RL in_BCL21 order_BCL22 to_TO take_VVI the_AT route_NN1 all_DB the_AT way_NN1 through_II the_AT three_MC phases_NN2 ._. 
</s>
<s>
Statistics_NN show_VV0 that_CST only_RR an_AT1 average_NN1 of_IO 18%_NNU of_IO drug_NN1 candidates_NN2 survive_VV0 from_II clinical_JJ phase_NN1 1_MC1 to_II registration_NN1 4_MC ._. 
</s>
<s>
This_DD1 means_VVZ that_CST the_AT optimisation_NN1 of_IO a_AT1 chemical_JJ process_NN1 maybe_RR wasted_VVN though_CS this_DD1 risk_NN1 has_VHZ to_TO be_VBI accepted_VVN as_CSA generally_RR the_AT alternative_JJ processes_NN2 in_II many_DA2 cases_NN2 deliver_VV0 the_AT required_JJ quantities_NN2 faster_RRR and_CC at_II much_RR lower_JJR prices_NN2 ._. 
</s>
<s>
The_AT venture_NN1 to_II early_JJ optimisation_NN1 can_VM often_RR pay_VVI off_RP later_RRR on_RP ._. 
</s>
<s>
Tony_NP1 Y._NP1 Zhang_NP1 ,_, Process_VV0 Chemistry_NN1 :_: The_AT Science_NN1 ,_, Business_NN1 ,_, Logic_NN1 and_CC Logistics_NN1 ,_, Chem_NP1 ._. 
</s>
<s>
Rev._NNB 2006_MC ,_, 106_MC ,_, 2583-2595_MCMC ._. 
</s>
<s>
The_AT ideal_JJ process_NN1 should_VM be_VBI safe_JJ ,_, ecologically_RR sound_VV0 ,_, reproducible_JJ both_RR on_II repetitive_JJ runs_NN2 and_CC on_II scale_NN1 up_RP ,_, fit_VV0 the_AT plant_NN1 physically_RR ,_, produce_VV0 product_NN1 of_IO high_JJ quality_NN1 that_CST passes_VVZ predetermined_JJ specification_NN1 and_CC be_VBI economical_JJ ._. 
</s>
<s>
However_RR there_EX is_VBZ no_AT ideal_JJ process_NN1 and_CC the_AT best_RRT that_DD1 can_VM be_VBI done_VDN is_VBZ to_TO approach_VVI the_AT ideal_JJ although_CS compromises_NN2 would_VM still_RR have_VHI to_TO be_VBI made_VVN ._. 
</s>
<s>
Impurities_NN2 are_VBR an_AT1 important_JJ factor_NN1 to_TO consider_VVI in_II a_AT1 process_NN1 ._. 
</s>
<s>
If_CS impurities_NN2 exceed_VV0 the_AT limits_NN2 of_IO the_AT specifications_NN2 ,_, the_AT process_NN1 chemist_NN1 must_VM reduce_VVI these_DD2 by-products_NN2 or_CC eliminate_VV0 them_PPHO2 in_II an_AT1 extra_JJ purification_NN1 step_NN1 ._. 
</s>
<s>
An_AT1 unknown_JJ impurity_NN1 in_II the_AT final_JJ product_NN1 needs_VVZ to_TO be_VBI investigated_VVN ._. 
</s>
<s>
Firstly_RR ,_, the_AT by-product_NN1 is_VBZ isolated_VVN by_II prep_NN1 high-pressure_JJ liquid_JJ chromatography_NN1 (_( HPLC_NP1 )_) ,_, the_AT structure_NN1 is_VBZ determined_VVN by_II NMR_NP1 and_CC mass_JJ spectroscopy_NN1 ,_, a_AT1 mechanism_NN1 is_VBZ proposed_VVN for_IF its_APPGE formation_NN1 ,_, the_AT synthetic_JJ step_NN1 in_II which_DDQ this_DD1 forms_VVZ is_VBZ identified_VVN and_CC finally_RR the_AT reaction_NN1 conditions_NN2 are_VBR altered_VVN to_TO minimise_VVI the_AT formation_NN1 of_IO undesirable_JJ by-product_NN1 ._. 
</s>
<s>
Oljan_JJ Repic_NN1 ,_, Principles_NN2 of_IO process_NN1 research_NN1 and_CC chemical_JJ development_NN1 in_II the_AT Pharmaceutical_JJ Industry_NN1 ,_, Wiley-Interscience_NP1 publication_NN1 ,_, 1998_MC ,_, ch._NNU 1_MC1 ,_, pp._NNU2 5-12_MCMC ._. 
</s>
<s>
Oljan_JJ Repic_NN1 ,_, Principles_NN2 of_IO process_NN1 research_NN1 and_CC chemical_JJ development_NN1 in_II the_AT Pharmaceutical_JJ Industry_NN1 ,_, Wiley-Interscience_NP1 publication_NN1 ,_, 1998_MC ,_, ch._NNU 2_MC ,_, pp._NNU2 17-18_MCMC ._. 
</s>
<s>
Even_RR the_AT most_RGT simple_JJ discovery_NN1 routes_NN2 can_VM have_VHI issues_NN2 making_VVG scale_NN1 up_II difficult_JJ ,_, an_AT1 example_NN1 of_IO this_DD1 is_VBZ the_AT synthesis_NN1 of_IO benzthiophene_NN1 ._. 
</s>
<s>
The_AT initial_JJ medicinal_JJ chemistry_NN1 route_NN1 is_VBZ shown_VVN in_II figure_NN1 1_MC1 ,_, the_AT starting_NN1 material_NN1 used_VVN (_( 2-bromothiophenol_NN1 )_) is_VBZ very_RG expensive_JJ and_CC not_XX readily_RR available_JJ ._. 
</s>
<s>
This_DD1 could_VM be_VBI made_VVN in-house_JJ but_CCB that_DD1 would_VM mean_VVI going_VVG backwards_RL and_CC making_VVG the_AT route_NN1 longer_RRR which_DDQ is_VBZ not_XX desirable_JJ ,_, the_AT solution_NN1 would_VM be_VBI to_TO change_VVI the_AT route_NN1 ._. 
</s>
<s>
Lithiating_VVG thiophenol_NN1 is_VBZ a_AT1 much_RR cheaper_JJR option_NN1 and_CC then_RT forming_VVG the_AT dianion_NN1 of_IO thiophenol_NN1 provides_VVZ a_AT1 simple_JJ and_CC efficient_JJ solution_NN1 ._. 
</s>
<s>
Another_DD1 example_NN1 is_VBZ the_AT synthesis_NN1 of_IO Idoxifene_NP1 ,_, the_AT synthetic_JJ route_NN1 that_CST was_VBDZ originally_RR going_VVGK to_TO be_VBI used_VVN as_CSA shown_VVN in_II figure_NN1 2_MC ._. 
</s>
<s>
The_AT issues_NN2 with_IW this_DD1 route_NN1 are_VBR that_DD1 reagent_NN1 A_ZZ1 iodophenyl_NN1 lithium_NN1 has_VHZ a_AT1 half-life_NN1 of_IO around_RG 40_MC mins_NNT2 at_II -60_MC C_NP1 ,_, at_II a_AT1 1000L_NNU scale_NN1 butyl_NN1 lithium_NN1 would_VM take_VVI at_RR21 least_RR22 90_MC minutes_NNT2 to_TO add_VVI as_CSA it_PPH1 is_VBZ exothermic_JJ and_CC the_AT addition_NN1 of_IO the_AT ketone_NN1 would_VM take_VVI over_RG 2_MC hours_NNT2 ,_, by_II this_DD1 time_NNT1 the_AT butyl_NN1 lithium_NN1 would_VM have_VHI degraded_VVN ._. 
</s>
<s>
The_AT solution_NN1 to_II this_DD1 is_VBZ to_TO use_VVI the_AT 1,4-diiodobenzene_FO compound_VV0 to_TO form_VVI the_AT intermediate_JJ (_( figure_NN1 3_MC )_) ,_, the_AT addition_NN1 of_IO butyl_NN1 lithium_NN1 could_VM be_VBI around_RG 10_MC hours_NNT2 without_IW affecting_VVG the_AT yield_NN1 or_CC quality_NN1 and_CC changing_VVG the_AT solvent_NN1 allowed_VVD the_AT reaction_NN1 to_TO be_VBI carried_VVN out_RP at_II much_RR higher_JJR temperatures_NN2 ._. 
</s>
<s>
There_EX are_VBR many_DA2 factors_NN2 to_TO consider_VVI when_CS deciding_VVG on_II the_AT most_RGT viable_JJ route_NN1 ._. 
</s>
<s>
Normally_RR the_AT best_JJT route_NN1 is_VBZ the_AT cheapest_JJT but_CCB there_EX are_VBR other_JJ things_NN2 to_TO take_VVI in_II account_NN1 such_II21 as_II22 safety_NN1 ,_, health_NN1 and_CC environment_NN1 ,_, patents_NN2 (_( need_VV0 to_TO make_VVI sure_JJ no_AT other_JJ patents_NN2 are_VBR infringed_VVN )_) ,_, regulatory_JJ and_CC operability_NN1 factors_NN2 ._. 
</s>
<s>
Hans-Ruedi_NP1 Marti_NP1 ,_, Jay_NP1 ._. 
</s>
<s>
S._NP1 Siegel_NP1 ,_, Process_VV0 chemistry_NN1 in_II API_JJ development_NN1 ,_, Chimia_NP1 2006_MC ,_, 60_MC ,_, No_AT 9_MC ._. 
</s>
<s>
In_II the_AT optimisation_NN1 of_IO a_AT1 synthetic_JJ route_NN1 several_DA2 factors_NN2 need_VV0 to_TO be_VBI considered_VVN ,_, firstly_RR what_DDQ goes_VVZ above_II the_AT arrow_NN1 ;_; reagents_NN2 ,_, solvent_NN1 and_CC work-up/isolation_NN1 where_CS purification_NN1 and_CC purity_NN1 are_VBR controlled_VVN ;_; the_AT optimum_JJ conditions_NN2 ,_, including_II temperature_NN1 and_CC concentration_NN1 -_- very_RG concentrated_JJ reaction_NN1 leads_VVZ to_II a_AT1 cheaper_JJR and_CC quicker_JJR synthesis_NN1 ;_; the_AT critical_JJ parameters_NN2 and_CC what_DDQ their_APPGE ranges_NN2 are_VBR ._. 
</s>
<s>
In_II the_AT future_NN1 there_EX will_VM be_VBI an_AT1 increased_JJ pressure_NN1 to_TO get_VVI a_AT1 drug_NN1 to_TO market_VVI and_CC it_PPH1 is_VBZ hard_JJ to_TO move_VVI quickly_RR with_IW this_DD1 when_CS the_AT route_NN1 is_VBZ inefficient_JJ ,_, there_EX is_VBZ also_RR patent_JJ pressure_NN1 as_CSA they_PPHS2 only_RR last_MD 20_MC years_NNT2 ._. 
</s>
<s>
Less_DAR time_NNT1 to_TO develop_VVI the_AT process_NN1 will_VM push_VVI the_AT selection_NN1 earlier_RRR ,_, this_DD1 will_VM blend_VVI the_AT boundaries_NN2 between_II process_NN1 research_NN1 and_CC development_NN1 and_CC medicinal_JJ chemistry_NN1 ._. 
</s>
<s>
New_JJ technology_NN1 such_II21 as_II22 robots_NN2 wo_FU n't_XX solve_VV0 this_DD1 problem_NN1 alone_RR ,_, new_JJ reactions_NN2 ,_, better_RRR experimental_JJ design_NN1 and_CC more_DAR computer_NN1 power_NN1 will_VM all_DB have_VHI an_AT1 impact_NN1 on_II this_DD1 ._. 
</s>
<s>
When_CS developing_VVG the_AT manufacturing_NN1 route_NN1 to_II the_AT key_JJ intermediate_JJ in_II the_AT synthesis_NN1 of_IO ARC-123196_MC ,_, the_AT process_NN1 chemistry_NN1 team_NN1 at_II AZ_NP1 came_VVD across_II several_DA2 difficult_JJ steps_NN2 and_CC unfortunately_RR this_DD1 compound_NN1 was_VBDZ terminated_VVN at_II validation_NN1 ._. 
</s>
<s>
The_AT key_JJ chiral_JJ compounds_NN2 are_VBR shown_VVN in_II figure_NN1 4_MC along_II21 with_II22 the_AT final_JJ compound_NN1 to_TO be_VBI synthesised_VVN ARC-123196_MC ._. 
</s>
<s>
This_DD1 final_JJ compound_NN1 was_VBDZ a_AT1 candidate_NN1 drug_NN1 for_IF inflammatory_JJ and_CC allergic_JJ conditions_NN2 ;_; a_AT1 key_JJ structural_JJ feature_NN1 is_VBZ the_AT optically_RR pure_JJ chiral_JJ hydroxyl_NN1 pyridine_NN1 ._. 
</s>
<s>
Two_MC initial_JJ routes_NN2 were_VBDR considered_VVN both_RR starting_VVG from_II the_AT dihydroxy_JJ pyridine_NN1 4_MC ,_, one_MC1 via_II the_AT formation_NN1 of_IO an_AT1 epoxide_NN1 then_RT forming_VVG intermediate_JJ 7_MC which_DDQ could_VM then_RT go_VVI on_RP to_II synthesise_NN1 the_AT active_JJ pharmaceutical_JJ ingredient_NN1 (_( API_NP1 )_) ,_, or_CC via_II an_AT1 electrophilic_JJ cyclic_JJ carbonate_NN1 to_TO form_VVI the_AT same_DA intermediate_JJ 7_MC ._. 
</s>
<s>
There_EX were_VBDR two_MC problems_NN2 encountered_VVN with_IW this_DD1 synthesis_NN1 ;_; firstly_RR the_AT starting_NN1 material_NN1 is_VBZ a_AT1 viscous_JJ liquid_NN1 and_CC therefore_RR was_VBDZ difficult_JJ to_TO handle_VVI especially_RR on_II a_AT1 large_JJ scale_NN1 ;_; secondly_RR route_NN1 1_MC1 is_VBZ not_XX cis_NN1 selective_JJ through_II tosylation_NN1 and_CC so_RR route_NN1 2_MC is_VBZ the_AT preferred_JJ route_NN1 to_TO form_VVI intermediate_JJ 7_MC ._. 
</s>
<s>
The_AT next_MD stage_NN1 in_II the_AT process_NN1 is_VBZ to_TO consider_VVI whether_CSW to_TO perform_VVI a_AT1 linear_JJ or_CC convergent_JJ synthetic_JJ approach_NN1 to_TO complete_VVI the_AT synthesis_NN1 of_IO the_AT final_JJ compound_NN1 ._. 
</s>
<s>
The_AT retrosynthesis_NN1 for_IF the_AT linear_JJ approach_NN1 is_VBZ shown_VVN in_II figure_NN1 6_MC ._. 
</s>
<s>
One_MC1 of_IO the_AT main_JJ problems_NN2 with_IW this_DD1 approach_NN1 is_VBZ that_CST there_EX is_VBZ a_AT1 further_JJR five_MC stages_NN2 after_II the_AT synthesis_NN1 of_IO the_AT carbonate_NN1 ,_, this_DD1 is_VBZ a_AT1 lengthy_JJ synthesis_NN1 involving_VVG protecting_JJ and_CC de-protecting_VVG groups_NN2 and_CC is_VBZ not_XX really_RR ideal_JJ ._. 
</s>
<s>
The_AT synthesis_NN1 of_IO compound_NN1 6_MC is_VBZ also_RR lengthy_JJ ,_, a_AT1 total_NN1 of_IO 6_MC steps_NN2 which_DDQ is_VBZ not_XX cost_VV0 effective_JJ ._. 
</s>
<s>
Generally_RR the_AT linear_JJ approach_NN1 is_VBZ not_XX used_VVN ,_, as_CSA it_PPH1 is_VBZ not_XX time_NNT1 efficient_JJ ._. 
</s>
<s>
The_AT convergent_JJ approach_NN1 uses_VVZ parallel_JJ processing_NN1 synthesising_VVG two_MC intermediates_NN2 at_II the_AT same_DA time_NNT1 ._. 
</s>
<s>
The_AT process_NN1 chemistry_NN1 team_NN1 can_VM also_RR outsource_VVI the_AT production_NN1 of_IO one_MC1 of_IO these_DD2 two_MC intermediates_NN2 which_DDQ can_VM make_VVI the_AT synthesis_NN1 more_DAR time_NNT1 efficient_JJ ._. 
</s>
<s>
Using_VVG the_AT convergent_JJ approach_NN1 is_VBZ more_RGR desirable_JJ than_CSN the_AT linear_JJ however_RR again_RT several_DA2 points_NN2 need_VV0 to_TO be_VBI considered_VVN ._. 
</s>
<s>
The_AT sulphonamide_NN1 on_II compound_NN1 8_MC needs_NN2 to_TO be_VBI protected_VVN as_CSA attack_NN1 of_IO the_AT oxygen_NN1 vs._II nitrogen_NN1 at_II the_AT carbonate_NN1 requires_VVZ control_NN1 ._. 
</s>
<s>
There_EX are_VBR also_RR several_DA2 synthetic_JJ methods_NN2 to_TO form_VVI the_AT biaryl_NN1 8_MC which_DDQ needed_VVD to_TO be_VBI assessed_VVN utilizing_VVG metal-catalysed_JJ couplings_NN2 ;_; Stille_NP1 ,_, Negishi_NP1 ,_, Suzuki_NP1 ,_, Kumada_NP1 ,_, etc_RA ._. 
</s>
<s>
The_AT Stille_NP1 reaction_NN1 uses_VVZ organo-tin_NN1 reagents_NN2 which_DDQ are_VBR difficult_JJ to_TO remove_VVI and_CC toxic_JJ ,_, the_AT Suzuki_NP1 reaction_NN1 is_VBZ utilized_VVN instead_RR ._. 
</s>
<s>
The_AT Suzuki_NP1 reaction_NN1 uses_VVZ Pd_NP1 0_MC in_II the_AT metal-catalysed_JJ coupling_NN1 however_RR as_CSA this_DD1 is_VBZ air_NN1 sensitive_JJ so_CS it_PPH1 is_VBZ generated_VVN insitu_NN1 ._. 
</s>
<s>
The_AT mechanism_NN1 is_VBZ similar_JJ to_II the_AT Sille_NP1 coupling_NN1 ;_; oxidative_JJ addition_NN1 of_IO the_AT aromatic_JJ halide_NN1 to_II the_AT palladium_NN1 (_( 0_MC )_) complex_NN1 generates_VVZ a_AT1 palladium_NN1 (_( II_MC )_) intermediate_JJ ._. 
</s>
<s>
This_DD1 then_RT under_RP goes_VVZ a_AT1 transmetallation_NN1 with_IW the_AT boronate_JJ species_NN ,_, from_II which_DDQ the_AT product_NN1 is_VBZ released_VVN by_II reductive_JJ eliminate_VV0 ._. 
</s>
<s>
The_AT palladium_NN1 (_( 0_MC )_) catalyst_NN1 is_VBZ regenerated_VVN during_II this_DD1 process_NN1 ._. 
</s>
<s>
This_DD1 is_VBZ the_AT route_NN1 used_VVN in_II the_AT synthesis_NN1 of_IO compound_NN1 8_MC with_IW a_AT1 yield_NN1 of_IO 85%_NNU ._. 
</s>
<s>
The_AT compound_NN1 produced_VVN is_VBZ protected_VVN at_II the_AT nitrogen_NN1 ;_; this_DD1 bulky_JJ group_NN1 sterically_RR hinders_VVZ any_DD nucleophilic_JJ attack_NN1 by_II the_AT amide_NN1 ._. 
</s>
<s>
A_AT1 palladium_NN1 scavenger_NN1 was_VBDZ needed_VVN to_TO remove_VVI remaining_JJ palladium_NN1 ._. 
</s>
<s>
The_AT deloxan_JJ resin_NN1 was_VBDZ an_AT1 effective_JJ scavenger_NN1 reducing_VVG the_AT palladium_NN1 content_NN1 from_II 240ppm_NNU to_II 2ppm_NNU after_II treatment_NN1 with_IW the_AT resin_NN1 ._. 
</s>
<s>
J._NP1 Clayden_NP1 ,_, N._NP1 Greeves_NP1 ,_, S._NP1 Warren_NP1 ,_, P._NP1 Wothers_NP1 ,_, Organic_JJ chemistry_NN1 ,_, 2001_MC ,_, ch._NNU 48_MC ,_, pp._NNU2 1328-1329_MCMC ._. 
</s>
<s>
The_AT synthesis_NN1 of_IO the_AT pyridine_NN1 diol_NN1 carbonate_NN1 6_MC was_VBDZ first_MD carried_VVD out_RP using_VVG the_AT medicinal_JJ chemistry_NN1 route_NN1 producing_VVG multi_JJ kilo_NNU1 quantities_NN2 ._. 
</s>
<s>
The_AT oxalate_NN1 salt_NN1 is_VBZ produced_VVN which_DDQ gives_VVZ a_AT1 solid_JJ and_CC makes_VVZ handling_VVG easier_RRR ._. 
</s>
<s>
Although_CS this_DD1 is_VBZ a_AT1 lengthy_JJ route_NN1 it_PPH1 gives_VVZ high_JJ purity_NN1 99%_NNU and_CC an_AT1 ee_UH of_IO 99%_NNU ._. 
</s>
<s>
The_AT dimethyl_NN1 carbonate_NN1 reagent_NN1 used_VVN in_II the_AT preparation_NN1 of_IO the_AT carbonate_NN1 is_VBZ cheap_JJ and_CC readily_RR available_JJ and_CC the_AT methanol_NN1 is_VBZ distilled_VVN off_RP as_CSA this_DD1 causes_VVZ the_AT reverse_JJ reaction_NN1 to_TO occur_VVI ._. 
</s>
<s>
Developed_VVN in_II partnership_NN1 with_IW Evotec_NP1 OIA_NP1 ._. 
</s>
<s>
The_AT next_MD stage_NN1 in_II the_AT synthesis_NN1 of_IO ARC-123196_MC was_VBDZ to_TO combine_VVI the_AT two_MC main_JJ components_NN2 (_( compounds_VVZ 6_MC and_CC 8_MC )_) to_TO produce_VVI the_AT first_MD multi-kilo_JJ batch_NN1 ._. 
</s>
<s>
The_AT first_MD step_NN1 was_VBDZ to_TO make_VVI the_AT free_JJ base_NN1 of_IO compound_NN1 6_MC via_II salt_NN1 exchange_NN1 then_RT the_AT protected_JJ compound_NN1 8_MC was_VBDZ added_VVN to_TO form_VVI the_AT intermediate_JJ 9_MC ._. 
</s>
<s>
The_AT optimal_JJ conditions_NN2 for_IF this_DD1 reaction_NN1 were_VBDR found_VVN to_TO be_VBI 1eq_FO CsCO_NP1 3_MC ,_, 1eq_FO biaryl_NN1 ,_, 1eq_FO pyridyl_NN1 carbonate_NN1 in_II 16_MC volumes_NN2 of_IO N-methyl_JJ pyrrolidinone_NN1 (_( NMP_NP1 )_) ._. 
</s>
<s>
The_AT product_NN1 was_VBDZ isolated_VVN as_II an_AT1 ethyl_NN1 acetate_NN1 solution_NN1 which_DDQ is_VBZ then_RT ready_JJ for_IF de-protection_NN1 of_IO the_AT nitrogen_NN1 ._. 
</s>
<s>
De-protection_NN1 of_IO the_AT nitrogen_NN1 was_VBDZ carried_VVN out_RP producing_VVG the_AT HCl_NP1 salt_NN1 ,_, as_CSA this_DD1 can_VM readily_RR dissociate_VVI ,_, it_PPH1 is_VBZ unstable_JJ and_CC therefore_RR the_AT free_JJ base_NN1 needs_VVZ to_TO be_VBI obtained_VVN ._. 
</s>
<s>
The_AT salt_NN1 was_VBDZ obtained_VVN in_II a_AT1 disappointing_JJ 54%_NNU yield_NN1 however_RR ;_; the_AT yield_NN1 of_IO the_AT free_JJ base_NN1 was_VBDZ moderately_RR improved_VVN to_II 62%_NNU with_IW purity_NN1 in_II the_AT region_NN1 of_IO 97%_NNU ._. 
</s>
<s>
This_DD1 synthetic_JJ route_NN1 to_TO form_VVI the_AT product_NN1 ARC-123196_MC is_VBZ reasonable_JJ and_CC was_VBDZ used_VVN to_TO produce_VVI the_AT product_NN1 on_II a_AT1 multi_JJ kilo_NNU1 scale_NN1 ._. 
</s>
<s>
The_AT route_NN1 to_II forming_VVG the_AT biaryl_NN1 compound_NN1 8_MC uses_VVZ cheap_JJ and_CC readily_RR available_JJ starting_NN1 material_NN1 and_CC is_VBZ economically_RR viable_JJ ._. 
</s>
<s>
The_AT overall_JJ convergent_JJ synthesis_NN1 from_II the_AT carbonate_NN1 and_CC biaryl_NN1 is_VBZ scalable_JJ and_CC operationally_RR simple_JJ ._. 
</s>
<s>
However_RR as_CSA stated_VVN before_II the_AT carbonate_NN1 does_VDZ not_XX have_VHI an_AT1 economic_JJ supply_NN1 route_NN1 ._. 
</s>
<s>
To_TO make_VVI this_DD1 synthesis_NN1 more_RGR efficient_JJ and_CC economically_RR viable_JJ this_DD1 needed_VVD to_TO be_VBI developed_VVN further_RRR ._. 
</s>
<s>
The_AT first_MD route_NN1 used_VVN (_( see_VV0 figure_NN1 9_MC )_) to_TO produce_VVI the_AT carbonate_NN1 had_VHD expensive_JJ starting_NN1 material_NN1 ,_, the_AT intermediate_JJ aldehyde_NN1 is_VBZ prone_JJ to_II polymerisation_NN1 and_CC epimerisation_NN1 ,_, gulonolactone_NN1 is_VBZ very_RG expensive_JJ and_CC wasteful_JJ as_CSA only_RR three_MC carbons_NN2 are_VBR used_VVN ._. 
</s>
<s>
This_DD1 initial_JJ route_NN1 was_VBDZ used_VVN to_TO prepare_VVI 84g_NNU of_IO the_AT carbonate_NN1 with_IW the_AT cost_NN1 of_IO the_AT oxalate_NN1 salt_NN1 at_II 16K_FO per_II Kg_NNU ._. 
</s>
<s>
After_CS careful_JJ consideration_NN1 and_CC several_DA2 attempts_NN2 by_II the_AT process_NN1 chemistry_NN1 team_NN1 -_- the_AT developed_JJ route_NN1 used_VMK to_TO produce_VVI the_AT carbonate_NN1 utilises_VVZ the_AT Heck_NN1 reaction_NN1 ._. 
</s>
<s>
This_DD1 couples_VVZ together_RL a_AT1 halide_NN1 and_CC an_AT1 alkene_NN1 to_TO form_VVI a_AT1 new_JJ alkene_NN1 ._. 
</s>
<s>
The_AT mechanism_NN1 involves_VVZ oxidative_JJ addition_NN1 of_IO the_AT halide_NN1 ,_, insertion_NN1 of_IO the_AT olefin_NN1 followed_VVN by_II elimination_NN1 of_IO the_AT product_NN1 by_II a_AT1 -_- hydride_VV0 elimination_NN1 process_NN1 ._. 
</s>
<s>
The_AT palladium_NN1 (_( 0_MC )_) catalyst_NN1 is_VBZ then_RT regenerated_VVN by_II a_AT1 base_NN1 ._. 
</s>
<s>
J._NP1 Clayden_NP1 ,_, N._NP1 Greeves_NP1 ,_, S._NP1 Warren_NP1 ,_, P._NP1 Wothers_NP1 ,_, Organic_JJ chemistry_NN1 ,_, 2001_MC ,_, ch._NNU 48_MC ,_, pp._NNU2 1321-1322_MCMC ._. 
</s>
<s>
Two_MC products_NN2 were_VBDR produced_VVN 10_MC and_CC 11_MC in_II this_DD1 reaction_NN1 ._. 
</s>
<s>
Using_VVG initial_JJ conditions_NN2 from_II a_AT1 published_JJ journal_NN1 ,_, the_AT ratio_NN1 of_IO products_NN2 was_VBDZ 13:1_MC (_( compounds_VVZ 10_MC :_: compound_VV0 11_MC )_) however_RR after_II changing_VVG the_AT conditions_NN2 slightly_RR and_CC performing_VVG an_AT1 aqueous_JJ wash_NN1 to_TO eliminate_VVI the_AT impurity_NN1 the_AT ratio_NN1 was_VBDZ 18:1_MC ._. 
</s>
<s>
The_AT crude_JJ material_NN1 was_VBDZ isolated_VVN in_II 60-65%_FO yield_VV0 with_IW purity_NN1 of_IO 94%_NNU ,_, the_AT next_MD step_NN1 involved_VVD asymmetric_JJ hydrogenation_NN1 using_VVG an_AT1 enantioselective_JJ ruthenium_NN1 bisphosphine_NN1 catalyst_NN1 and_CC then_RT final_JJ conversion_NN1 to_TO compound_VVI 6_MC ._. 
</s>
<s>
This_DD1 route_NN1 was_VBDZ used_VVN successfully_RR to_TO prepare_VVI multi_JJ kilo_NNU1 scale_NN1 in_II the_AT large-scale_JJ lab_NN1 ._. 
</s>
<s>
Marie-Claude_NP1 Viaud_NP1 ,_, Patricia_NP1 Jamoneau_NP1 ,_, Laurence_NP1 Savelon_NP1 ,_, and_CC Gerald_NP1 Guillaumet_NP1 ,_, Substituted_VVN oxazolo&lsqb;4,5-b&rsqb;pyridin-2_FO (_( 3H_FO )_) -ones_NN2 :_: Functionalisation_NN1 at_II 6-position_NN1 ,_, Tet_NP1 ._. 
</s>
<s>
Lett._NP1 ,_, 1996_MC ,_, 2409-2412_MCMC ._. 
</s>
<s>
Developed_VVN in_II partnership_NN1 with_IW PPG_NP1 SIPSY_NP1 ._. 
</s>
<s>
This_DD1 gave_VVD the_AT carbonate_NN1 in_II 35%_NNU yield_NN1 but_CCB with_IW 97%_NNU purity_NN1 and_CC 98%_NNU ee_UH ,_, the_AT route_NN1 was_VBDZ not_XX fully_RR optimised_VVN but_CCB is_VBZ a_AT1 viable_JJ route_NN1 for_IF scale_NN1 up_RP ._. 
</s>
<s>
The_AT overall_JJ synthetic_JJ route_NN1 that_CST could_VM have_VHI been_VBN used_VVN to_TO synthesise_VVI ARC-123196_MC is_VBZ shown_VVN below_RG however_RR after_II phase_NN1 I_PPIS1 the_AT compound_NN1 was_VBDZ abandoned_VVN ._. 
</s>
<s>
The_AT route_NN1 developed_VVN by_II the_AT process_NN1 chemistry_NN1 team_NN1 is_VBZ commercially_RR attractive_JJ and_CC would_VM have_VHI been_VBN used_VVN if_CS the_AT compound_NN1 had_VHD been_VBN taken_VVN on_RP further_RRR ._. 
</s>
<s>
The_AT process_NN1 research_NN1 and_CC development_NN1 department_NN1 play_VV0 an_AT1 important_JJ role_NN1 in_II the_AT production_NN1 of_IO a_AT1 new_JJ chemical_JJ entity_NN1 ._. 
</s>
<s>
Their_APPGE two_MC major_JJ aims_NN2 are_VBR to_TO produce_VVI all_DB the_AT drug_NN1 substance_NN1 needed_VVN by_II various_JJ other_JJ departments_NN2 throughout_II a_AT1 5-10_MCMC year_NNT1 period_NN1 and_CC the_AT second_NNT1 is_VBZ to_TO develop_VVI a_AT1 process_NN1 which_DDQ is_VBZ more_RGR efficient_JJ and_CC cost_VV0 effective_JJ ._. 
</s>
<s>
The_AT process_NN1 must_VM run_VVI under_II Good_JJ Management_NN1 Practice_NN1 (_( cGMP_NNU )_) guidelines_NN2 ._. 
</s>
<s>
As_CSA in_II the_AT example_NN1 given_VVN not_XX all_DB lead_VV0 compounds_NN2 make_VV0 it_PPH1 to_II the_AT final_JJ stages_NN2 ,_, however_RRQV it_PPH1 is_VBZ important_JJ to_TO optimise_VVI the_AT process_NN1 of_IO an_AT1 API_NN1 early_RR on_RP as_CSA this_DD1 may_VM well_RR pay_VVI off_RP later_RRR on_RP and_CC decrease_VVI the_AT time_NNT1 to_II production_NN1 and_CC eventual_JJ launch_NN1 ._. 
</s>
